Business Context and Reporting Period
Company: Ispire Technology Inc. (ISPR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2026
Business Overview: Ispire engages in the R&D, design, and distribution of branded e-cigarettes and cannabis vaping hardware. The company operates globally, with significant manufacturing and sales operations in Hong Kong, Malaysia, and the U.S. It recently secured full licensure in Malaysia to manufacture nicotine vapor products.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2026 |
Nine Months Ended March 31, 2026 |
|---|---|---|
| Revenue | $18.69 million | $69.32 million |
| Gross Profit | $1.99 million | $10.61 million |
| Gross Margin | 10.7% | 15.3% |
| Net Loss | $(9.52) million | $(19.38) million |
| Net Loss Per Share (Basic/Diluted) | $(0.17) | $(0.34) |
| Cash and Restricted Cash | $18.08 million | (Balance Sheet: $18.03 million) |
| Total Debt (Current + Non-Current) | $1.09 million | $1.09 million |
| Related Party Payables | $73.16 million | $73.16 million |
Note: Related party payables consist of $38.16 million in current accounts payable and $35.00 million in non-current amounts due to Shenzhen Yi Jia, a supplier owned by the Company's Chairman.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 28.7% year-over-year (YoY) for the quarter and 35.4% for the nine-month period. The decline was driven by reduced sales in North America (due to stricter credit terms) and Europe (competitive market conditions).
- Margin Compression: Gross margin fell from 18.2% to 10.7% for the quarter and from 18.8% to 15.3% for the nine-month period. This was attributed to a shift in product mix toward lower-margin items and increased inventory impairment charges ($2.39 million for the nine months ended March 31, 2026, compared to $0.07 million in the prior year).
- Expense Reduction: Operating expenses decreased significantly, down 25.3% for the quarter and 31.6% for the nine-month period, primarily due to reduced headcount in North America, lower stock-based compensation, and decreased marketing spend.
- Credit Losses: Credit loss expenses remained high but decreased slightly YoY ($5.56 million for the quarter vs. $6.10 million prior year), reflecting ongoing collection challenges and write-offs.
- Stockholders' Equity: The company moved from positive equity ($0.60 million) at June 30, 2025, to a deficit of $(16.20) million at March 31, 2026, due to accumulated losses.
Guidance, Outlook, and Risks
- Outlook: Management expects to achieve positive cash flow in the first half of fiscal year 2027, driven by operating expense reductions, revenue generation from the new Malaysia facility, and cash flow from Hong Kong operations.
- Malaysia Operations: Ispire Malaysia received full licensure in March 2026 to manufacture nicotine vapor products. Production is expected to commence in June 2026. The company anticipates cost advantages over Chinese manufacturing due to the cancellation of China's 13% export VAT rebate for nicotine products.
- Joint Venture (IKE Tech): The company holds a 40% interest in IKE Tech LLC, focused on age-verification technology for vaping devices. IKE submitted a "component" PMTA to the FDA in April 2025. Success of this submission is critical for the value of the investment and potential market access for flavored products.
- Regulatory Risks: Significant risks include FDA PMTA approvals for U.S. products, evolving regulations in Europe (TPD), and potential bans or restrictions on cannabis and nicotine products globally.
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses in evaluating significant estimates (inventory and credit loss reserves), lack of accounting personnel, and IT general control deficiencies.
Investor Verification Checklist
- Cash Burn Rate: Verify the timeline to positive cash flow given the current net loss of ~$19.4 million for the nine-month period and cash balance of ~$18 million.
- Related Party Dependence: Assess the risk associated with $73.16 million in payables to a related party (Shenzhen Yi Jia), which represents a significant portion of total liabilities.
- Inventory Valuation: Review the $2.39 million inventory impairment charge and the methodology for future reserves, especially given the material weakness in internal controls regarding inventory estimates.
- Accounts Receivable Quality: Scrutinize the $21.5 million allowance for credit losses and the collectability of the remaining $28.6 million in net receivables.
- Joint Venture Viability: Monitor the status of the IKE Tech LLC FDA PMTA submission and the potential for further capital calls or dilution in the joint venture.